Regenerative Endodontics: Stem Cell Therapy and Revitalization Techniques

Regenerative endodontics (RE) aims to replace damaged pulp-dentin complex via biologically based procedures that restore function, vitality, and continued root development in necrotic immature teeth. Core principle: harness endogenous stem cells (SCs), signaling molecules, and scaffolds to regenerate functional pulp-like tissue. Key SC sources: dental pulp stem cells (DPSCs), stem cells from apical papilla (SCAP), periodontal ligament stem cells (PDLSCs), dental follicle progenitor cells (DFPCs), and bone marrow mesenchymal SCs (BM-MSCs). SCAP critical in immature teeth due to location at root apex and role in root maturation. Revitalization procedures (RP) clinically synonymous with RE but often lack true regeneration; instead promote canal revascularization and deposition of cementum-like or bone-like tissue. RP protocol: minimal debridement (NaOCl ≤1.5%, EDTA), intracanal medicament (triple antibiotic paste—TAP: ciprofloxacin, metronidazole, minocycline; or Ca(OH)₂), induction of apical bleeding to form scaffold clot, coronal seal (MTA). TAP concerns: discoloration (minocycline), cytotoxicity, antibiotic resistance; alternatives: double antibiotic paste (DAP), bioceramics (e.g., Biodentine), novel peptides. Clot serves as natural fibrin scaffold; limitations: inconsistent cell homing, poor vascularization, fibrous tissue dominance. Growth factors (GFs): key regulators—BMPs (BMP-2, -7), TGF-β1, VEGF, FGF-2, PDGF. GF delivery challenges: short half-life, off-target effects; solutions: nanoparticle carriers, hydrogels (e.g., alginate, chitosan), affinity-based systems. Scaffolds: synthetic (PLGA, PCL) vs natural (collagen, fibrin, hyaluronic acid); ideal scaffold: biocompatible, biodegradable, porous, mechanically stable, GF-binding capacity. In vivo studies: SCAP + hydrogel + BMP-2 → vascularized pulp-like tissue with odontoblast-like cells and tubular dentin formation. Challenges: immune response, bacterial contamination, pulp space infection, unpredictable revascularization. Diagnostics: CBCT for 3D root morphology, LDF (laser Doppler flowmetry) and PBPM (pulse oximetry) for vascular assessment; absence of sensory response despite vascularity common. Current SoA: no standardized protocol; success rates ~70–90% for RP (thickening walls, length increase, apical closure) but histologic regeneration rare. Emerging tech: 3D bioprinting of SC-laden constructs, gene-activated matrices (GAMs), exosome-based therapies (e.g., DPSC-derived exosomes carry miRNAs promoting angiogenesis, anti-apoptosis). Hypoxic preconditioning enhances SC survival and paracrine signaling. Autologous vs allogeneic SCs: autologous avoids rejection but limited cell yield; allogeneic (e.g., dental pulp cell banks) offer scalability but require immunomodulation. Clinical indications: immature permanent teeth with pulp necrosis (trauma, caries), apexogenesis failure, apical periodontitis. Contraindications: insufficient apical diameter (<1 mm), poor compliance, systemic immunocompromise. Long-term outcomes: reduced fracture risk vs apexification, but durability of regenerated tissue unknown. Regulatory landscape: FDA/EMA classify tissue-engineered products as ATMPs (advanced therapy medicinal products); few RE products approved (e.g., NuvOss® for bone, not pulp). Ethical issues: stem cell sourcing, pediatric consent, commercialization. Future: smart scaffolds with controlled GF release, in situ tissue engineering (recruit host SCs), microbiome modulation, machine learning (ML) models for outcome prediction. Pitfalls: misinterpretation of radiographic healing as regeneration, overuse in mature teeth, inadequate disinfection leading to failure, poor coronal seal causing microleakage. Best practices: strict asepsis, biomechanical preparation ≤apical third, avoid overinstrumentation, use of bioceramic sealers, final restoration with bonded core. Research gaps: long-term histology, optimal GF combinations, SC delivery methods, cost-effectiveness. In summary, RE represents paradigm shift from biomechanical obturation to biological restoration; RP is clinical gateway but true regeneration remains aspirational. Integration of SC biology, biomaterials, and clinical technique essential for next-gen endodontics.